Renal Impairment and Late Toxicities Comparing Contemporary Chemotherapy Regimens for Testicular Cancer in a Real-World Setting
This multicenter, real-world study shows that long-term CBM scores after NCCN-endorsed EPx4 or BEPx3 are comparable, but statistically significant differences in cisplatin-related toxicities exist. Cisplatin dose-dependent reductions in eGFR are followed by significant excesses of hypertension, hyperlipidemia, and CVD.
Authors
- David J. Vaughn (ORCID: https://orcid.org/0000-0002-7319-7719)
- Paul C. Dinh (ORCID: https://orcid.org/0000-0003-0235-8519)
- Clark Fung
- Sarah Kerns
- Lois Travis
- Howard D Sesso
- Neil E Martin
- Robert J. Hamilton
- Patrick O. Monahan
- Lawrence H. Einhorn
- Christian Kollmannsberger
- Darren R. Feldman
Institutions
- Brigham and Women's Hospital (US)
- University Health Network (CA)
- Memorial Sloan Kettering Cancer Center (US)
- University of British Columbia (CA)
- University of Toronto (CA)
- Medical College of Wisconsin (US)
- Cornell University (US)
- Princess Margaret Cancer Centre (CA)
- University of Rochester Medical Center (US)
- Dana-Farber Cancer Institute (US)
- Indiana University School of Medicine
- Indiana University – Purdue University Indianapolis (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- Journal of the National Comprehensive Cancer Network
- Published
- 2026-02-13
- DOI
- https://doi.org/10.6004/jnccn.2025.7120
- Primary Topic
- Testicular diseases and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00